Pharmacogenomics and genetic ancestry in Colombia: a study on all variant drug annotations of PharmGKB
Frontiers in Pharmacology · 29.08.2025 · 16
DOI: 10.3389/fphar.2025.1636451 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.08.2025. Verfasst von Andy A Acosta-Monterrosa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Exact and Natural Sciences, Universidad de Cartagena, Cartagena, Colombia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
To generate an ancestry-resolved pharmacogenomic (PGx) landscape for Colombia by integrating all PharmGKB variant-drug annotations with local allele-frequency data, thereby quantifying inter-ancestry differences of clinical relevance and exposing evidence gaps that hinder equitable precision medicine.
Methods
We conducted a cross-sectional analysis of 4,462 PharmGKB variant annotations (1994–2024), retaining 1,216 significant single-nucleotide polymorphisms (SNPs) reported in 552 studies. Allele frequencies were extracted for five Colombian populations: two predominantly African (Palenque [PLQ], Chocó [CHG]) and three predominantly European (ATQCES, ATQPGC, CLM), from the CÓDIGO database. Spearman correlations compared population-specific PGx profiles; SNPs with >25 percentage-point frequency differentials were tabulated.
Results
European ancestry dominated the global evidence base, representing 51.5% of 651,532 participants, while African ancestry accounted for only 0.46% (n = 3,031). Strong correlations were observed among European-leaning Antioquians ( r 2 ≥ 0.90), whereas PLQ exhibited inverse or negligible correlations with those groups ( r 2 = −0.20 to −0.02) and minimal similarity with CHG ( r 2 = 0.12). Twenty-eight SNPs were frequent in PLQ (>75%) but rare in Europeans (<50%), and 44 showed the opposite pattern. Notable examples include CYP3A4 rs3735451-C (rivaroxaban; 87.1% vs. 23.2%), CYP3A5 rs776746-T (tacrolimus; 85% vs. 23.5%), and rs55881666-C (duloxetine; 15% vs. 84%). Globally, 71.5% of PGx studies originated in high-income countries.
Conclusion
Large, clinically actionable allele-frequency contrasts and pronounced discovery biases confirm the need for ancestry-aware PGx testing and locally calibrated dosing algorithms in Colombia. The analytic framework and variant catalogue generated knowledge to operationalize precision pharmacotherapy across admixed Latin-American populations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Exact and Natural Sciences, Universidad de Cartagena, Cartagena, Colombia.
- Center for Meta-Research and Scientometrics in Biomedical Sciences, Barranquilla, Colombia.
- Facultad de Ciencias para la Salud, Universidad de Manizales, Manizales, Colombia.
- Department of Health Sciences, Biomedical Scientometrics and Evidence-Based Research Unit, Universidad de la Costa, Barranquilla, Colombia.
- Facultad de Ciencias de la Salud, Centro de Investigaciones en Ciencias de la Vida, Universidad Simón Bolívar, Barranquilla, Colombia.
Zitieren
APA
Acosta-Monterrosa, A. A., Montoya-Quintero, K. F., Galván-Barrios, J., & Rojas Torres, I. L. (2025). Pharmacogenomics and genetic ancestry in Colombia: a study on all variant drug annotations of PharmGKB. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1636451
Vancouver
Acosta-Monterrosa AA, Montoya-Quintero KF, Galván-Barrios J, Rojas Torres IL. Pharmacogenomics and genetic ancestry in Colombia: a study on all variant drug annotations of PharmGKB. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1636451
BibTeX
@article{AcostaMonterrosa2025,
author = {Acosta-Monterrosa, Andy A and Montoya-Quintero, Kevin Fernando and Galván-Barrios, Johana and Rojas Torres, Indiana Luz},
title = {Pharmacogenomics and genetic ancestry in Colombia: a study on all variant drug annotations of PharmGKB},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1636451}
}
EUVIMED